APOA5 and hypertriglyceridemia: Based on the above, we hypothesized a mechanism for olanzapine-induced hypertriglyceridemia caused by the defects of sorting and secretion of hepatic apoA5, resulting in low plasma apoA5 levels, in which the dysfunctional signal peptide may be involved.